Cephalon, Inc. to Webcast R&D Day

FRAZER, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH)
today announced that its Research and Development Day in New York City, to be
held on November 10, 2009, will be webcast live on the investor relations
section of its website at http://www.cephalon.com.

Cephalon's senior management will review the company's product pipeline and
discuss research and development initiatives including its pipeline of
biologics from its recent acquisition of Arana Therapeutics. In addition,
guest speakers will present data on two investigational medications,
Lupuzor(TM), for the treatment of systemic lupus erythematosus and Ception
Therapeutics, Inc.'s lead compound, reslizumab, a humanized monoclonal
antibody (mAb) against interleukin-5 for the treatment of pediatric
eosinophilic esophagitis and eosinophilic asthma in adults. Cephalon holds an
option to acquire Ception.

The presentations will be delivered on Tuesday, November 10, 2009 beginning at
approximately 12:00 p.m. EST and ending at 3:00 p.m. EST. The webcast will be
archived for one week following the broadcast. To access the webcast, log on
to the company's website at www.cephalon.com and click on "Investors," then
"Webcast." Click on the link and follow the prompts for registration and
access.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company
dedicated to the discovery, development and commercialization of many unique
products in four core therapeutic areas: central nervous system, inflammatory
diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500
Index, Cephalon currently employs approximately 3,000 people in the United
States and Europe. U.S. sites include the company's headquarters in Frazer,
Pennsylvania, and offices, laboratories or manufacturing facilities in West
Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis,
Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The
Cephalon European headquarters and pre-clinical development center are located
in Maisons-Alfort, France, just outside of Paris. Key business units are
located in England, Ireland, France, Germany, Italy, Spain, the Netherlands
for the Benelux countries, and Poland for Eastern and Central European
countries. Cephalon Europe markets more than 30 products in four areas:
central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL®
(armodafinil) Tablets [C-IV], AMRIX® (cyclobenzaprine hydrochloride
extended-release capsules), TREANDA® (bendamustine hydrochloride) for
Injection, FENTORA® (fentanyl buccal tablet) [C-II], PROVIGIL® (modafinil)
Tablets [C-IV], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine
hydrochloride) and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. The
company also markets numerous products internationally. Full prescribing
information on its U.S. products is available at http://www.cephalon.com or by
calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press
release may contain forward-looking statements. Forward-looking statements
provide Cephalon's current expectations or forecasts of future events. These
may include statements regarding anticipated scientific progress on its
research programs; development of potential pharmaceutical products;
interpretation of clinical results; prospects for regulatory approval;
manufacturing development and capabilities; market prospects for its products;
sales, adjusted net income and basic adjusted income per common share
guidance; and other statements regarding matters that are not historical
facts. You may identify some of these forward-looking statements by the use of
words in the statements such as "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe" or other words and terms of similar meaning.
Cephalon's performance and financial results could differ materially from
those reflected in these forward-looking statements due to general financial,
economic, regulatory and political conditions affecting the biotechnology and
pharmaceutical industries as well as more specific risks and uncertainties
facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and
10-K filed with the U.S. Securities and Exchange Commission. Given these risks
and uncertainties, any or all of these forward-looking statements may prove to
be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Cephalon does not intend to update
publicly any forward-looking statement, except as required by law. The Private
Securities Litigation Reform Act of 1995 permits this discussion.

Contacts:
Media: Investors:
Sheryl Williams Robert (Chip) Merritt
610-738-6493 610-738-6376
swilliam@cephalon.com cmerritt@cephalon.com

SOURCE Cephalon, Inc.

Media: Sheryl Williams, +1-610-738-6493, swilliam@cephalon.com, or Investors:
Robert (Chip) Merritt, +1-610-738-6376, cmerritt@cephalon.com